Mirum Pharmaceuticals, Inc. $MIRM Holdings Decreased by Toth Financial Advisory Corp

Toth Financial Advisory Corp decreased its position in shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) by 93.3% during the third quarter, Holdings Channel.com reports. The institutional investor owned 685 shares of the company’s stock after selling 9,600 shares during the quarter. Toth Financial Advisory Corp’s holdings in Mirum Pharmaceuticals were worth $59,000 as of its most recent SEC filing.

Other institutional investors have also recently made changes to their positions in the company. Contravisory Investment Management Inc. lifted its stake in Mirum Pharmaceuticals by 2.3% in the second quarter. Contravisory Investment Management Inc. now owns 4,604 shares of the company’s stock worth $539,000 after acquiring an additional 103 shares during the period. ABS Investment Management LLC purchased a new position in Mirum Pharmaceuticals during the 2nd quarter valued at about $245,847,000. Faithward Advisors LLC raised its holdings in shares of Mirum Pharmaceuticals by 0.5% in the 1st quarter. Faithward Advisors LLC now owns 27,467 shares of the company’s stock valued at $2,537,000 after purchasing an additional 126 shares in the last quarter. Integrated Wealth Concepts LLC bought a new stake in shares of Mirum Pharmaceuticals in the 2nd quarter valued at about $27,000. Finally, Quantbot Technologies LP purchased a new stake in shares of Mirum Pharmaceuticals in the 2nd quarter worth approximately $44,000.

Analyst Upgrades and Downgrades

MIRM has been the topic of several research reports. Weiss Ratings raised shares of Mirum Pharmaceuticals from a “sell (d-)” rating to a “sell (d)” rating in a report on Thursday, August 6th. CLSA set a $146.00 target price on Mirum Pharmaceuticals in a research report on Monday, June 15th. Wall Street Zen downgraded Mirum Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Sunday, September 6th. Citigroup reissued a “buy” rating and issued a $160.00 price target (up from $145.00) on shares of Mirum Pharmaceuticals in a research report on Monday, September 28th. Finally, Citizens Jmp restated a “market outperform” rating and set a $137.00 price objective on shares of Mirum Pharmaceuticals in a research note on Thursday, August 27th. One research analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $143.81.

Mirum Pharmaceuticals Trading Up 5.7%

NASDAQ:MIRM opened at $86.01 on Friday. Mirum Pharmaceuticals, Inc. has a 52 week low of $63.23 and a 52 week high of $130.00. The firm has a 50 day moving average of $95.08 and a 200 day moving average of $100.89. The company has a quick ratio of 2.74, a current ratio of 2.86 and a debt-to-equity ratio of 1.28. The stock has a market capitalization of $5.58 billion, a price-to-earnings ratio of -5.91 and a beta of 0.61.

Mirum Pharmaceuticals (NASDAQ:MIRM) last released its quarterly earnings results on Wednesday, August 5th. The company reported ($1.06) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.74) by ($0.32). The firm had revenue of $176.24 million during the quarter, compared to analysts’ expectations of $166.33 million. Mirum Pharmaceuticals had a negative return on equity of 36.28% and a negative net margin of 139.18%. Mirum Pharmaceuticals’s revenue for the quarter was up 37.9% compared to the same quarter last year. During the same period in the prior year, the firm posted ($0.12) earnings per share. As a group, sell-side analysts anticipate that Mirum Pharmaceuticals, Inc. will post -1.31 earnings per share for the current fiscal year.

Insider Transactions at Mirum Pharmaceuticals

In related news, CEO Christopher Peetz sold 30,000 shares of the business’s stock in a transaction on Tuesday, September 1st. The stock was sold at an average price of $98.68, for a total transaction of $2,960,400.00. Following the transaction, the chief executive officer directly owned 194,440 shares in the company, valued at $19,187,339.20. The trade was a 13.37% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Jolanda Howe sold 658 shares of the company’s stock in a transaction dated Wednesday, September 2nd. The shares were sold at an average price of $100.00, for a total value of $65,800.00. Following the transaction, the senior vice president directly owned 616 shares in the company, valued at $61,600. This represents a 51.65% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 98,499 shares of company stock valued at $9,797,834 in the last quarter. 8.32% of the stock is currently owned by corporate insiders.

Mirum Pharmaceuticals Profile

Mirum Pharmaceuticals, Inc is a biopharmaceutical company focused on developing and commercializing medicines for rare diseases of the liver and gastrointestinal system. The company’s work centers on conditions involving impaired bile acid transport and cholestasis, which can cause serious liver damage and debilitating symptoms such as itching.

Mirum’s primary commercial product is Livmarli (maralixibat), an oral ileal bile acid transporter inhibitor. In the United States, Livmarli is approved to treat cholestatic pruritus associated with Alagille syndrome and progressive familial intrahepatic cholestasis in eligible pediatric patients.